Vitamin D Supplementation Decreases TGF-β1 Bioavailability in PCOS: A Randomized Placebo-Controlled Trial
| Autor: | Nitasha Julka, Oded Tal, Sara Irani, Devika Bhatt, Geralyn Lambert-Messerlian, Reshef Tal, Bharati Kalgi, Richard V. Grazi, David B. Seifer, Mohamad Irani |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Vitamin medicine.medical_specialty Adolescent Endocrinology Diabetes and Metabolism Clinical Biochemistry Placebo-controlled study Biological Availability Receptors Cell Surface Context (language use) Biochemistry vitamin D deficiency law.invention Transforming Growth Factor beta1 Young Adult chemistry.chemical_compound Endocrinology Randomized controlled trial Antigens CD law Internal medicine Vitamin D and neurology Humans Medicine Testosterone Prospective Studies Vitamin D Prospective cohort study Cholecalciferol Dehydroepiandrosterone Sulfate business.industry Biochemistry (medical) Endoglin Vitamins Vitamin D Deficiency medicine.disease Lipids Polycystic ovary Socioeconomic Factors chemistry Female Insulin Resistance business Polycystic Ovary Syndrome |
| Zdroj: | The Journal of Clinical Endocrinology & Metabolism. 100:4307-4314 |
| ISSN: | 1945-7197 0021-972X |
| DOI: | 10.1210/jc.2015-2580 |
| Popis: | There is an abnormal increase in TGF-β1 bioavailability in women with polycystic ovary syndrome (PCOS), which might play a role in the pathophysiology of this syndrome. Vitamin D (VD) supplementation improves various clinical manifestations of PCOS and decreases TGF-β1 levels in several diseases including myelofibrosis.The objective of the study was to determine the effect of VD supplementation on TGF-β1 bioavailability in VD-deficient women with PCOS and assess whether changes in TGF-β1/soluble endoglin (sENG) levels correlate with an improvement in PCOS clinical manifestations.This was a prospective, randomized, placebo-controlled trial.The study was conducted at an academic-affiliated medical center.Sixty-eight VD-deficient women with PCOS who were not pregnant or taking any exogenous hormones were recruited between October 2013 and January 2015.Forty-five women received 50 000 IU of oral vitamin D3 and 23 women received oral placebo once weekly for 8 weeks.Serum TGF-β1, sENG, lipid profile, testosterone, dehydroepiandrosterone sulfate, and insulin resistance were measured. The clinical parameters were evaluated before and 2 months after treatment.The VD level significantly increased and normalized after VD supplementation (16.3 ± 0.9 [SEM] to 43.2 ± 2.4 ng/mL; P.01), whereas it did not significantly change after placebo. After the VD supplementation, there was a significant decrease in the following: the interval between menstrual periods (80 ± 9 to 60 ± 6 d; P = .04), Ferriman-Gallwey score (9.8 ± 1.5 to 8.1 ± 1.5; P.01), triglycerides (138 ± 22 to 117 ± 20 mg/dL; P = .03), and TGF-β1 to sENG ratio (6.7 ± 0.4 to 5.9 ± 0.4; P = .04). In addition, the ΔTGF-β1 to sENG ratio was positively correlated with Δtriglycerides (r = 0.59; P = .03).VD supplementation in VD-deficient women with PCOS significantly decreases the bioavailability of TGF-β1, which correlates with an improvement in some abnormal clinical parameters associated with PCOS. This is a novel mechanism that could explain the beneficial effects of VD supplementation in women with PCOS. These findings may support new treatment modalities for PCOS, such as the development of anti-TGF-β drugs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|